Original Article
The association between adherence to elective nodal volume guidelines and reduced distant metastasis in esophageal and gastroesophageal junction cancer: a retrospective analysis of elective nodal irradiation
Journal of Gastrointestinal Oncology
2026;
17
(1)
:1
.
(28 February 2026)
Risk factors and prognostic implications of upper or middle mediastinal lymph nodes metastasis and recurrence in esophagogastric junction carcinoma
Journal of Gastrointestinal Oncology
2026;
17
(1)
:2
.
(28 February 2026)
Identification and validation of an explainable machine learning model for early postoperative pulmonary complications after esophagectomy in patients with esophageal cancer
Journal of Gastrointestinal Oncology
2026;
17
(1)
:3
.
(28 February 2026)
Private equity acquisitions of hospitals and the changing landscape of care for patients with gastrointestinal cancer
Journal of Gastrointestinal Oncology
2026;
17
(1)
:4
.
(28 February 2026)
Cadonilimab plus chemotherapy vs. PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study
Journal of Gastrointestinal Oncology
2026;
17
(1)
:5
.
(28 February 2026)
Training and validation of a nomogram for predicting synchronous distant organ metastasis in patients with very-early-onset colorectal cancer
Journal of Gastrointestinal Oncology
2026;
17
(1)
:6
.
(28 February 2026)
Construction of taurine metabolism-related risk model and subtype identification in colorectal cancer to predict prognosis and immunological features
Journal of Gastrointestinal Oncology
2026;
17
(1)
:7
.
(28 February 2026)
Non-surgical management of malignant bowel obstruction: strategies and outcomes in inoperable patients
Journal of Gastrointestinal Oncology
2026;
17
(1)
:8
.
(28 February 2026)
A hybrid molecular-imaging model for high-accuracy early colorectal cancer diagnosis
Journal of Gastrointestinal Oncology
2026;
17
(1)
:9
.
(28 February 2026)
A nine-gene nicotine-metabolism signature predicts prognosis and characterizes the immune landscape in colon adenocarcinoma
Journal of Gastrointestinal Oncology
2026;
17
(1)
:10
.
(28 February 2026)
Overstaging of the mesorectal fascia following neoadjuvant therapy and its impact on therapeutic management: a single-center retrospective cohort study of 506 mesorectal fascia positive patients
Journal of Gastrointestinal Oncology
2026;
17
(1)
:11
.
(28 February 2026)
ColoLDB: a machine learning-based predictive model for colorectal cancer using routine laboratory parameters
Journal of Gastrointestinal Oncology
2026;
17
(1)
:12
.
(28 February 2026)
Colon cancer cachexia remodels gut microbiota and metabolite profiles in a murine model
Journal of Gastrointestinal Oncology
2026;
17
(1)
:13
.
(28 February 2026)
Comparable survival outcome with anti-EGFR therapy in any treatment line in left-sided metastatic colorectal cancer
Journal of Gastrointestinal Oncology
2026;
17
(1)
:14
.
(28 February 2026)
Association of fruit and vegetable consumption with colorectal adenoma among adults in Korea: a cross-sectional study
Journal of Gastrointestinal Oncology
2026;
17
(1)
:15
.
(28 February 2026)
Clinicopathological characteristics and prognosis of patients with mucinous adenocarcinoma originating from the left colon, right colon, or rectum: a nationwide retrospective study in China
Journal of Gastrointestinal Oncology
2026;
17
(1)
:16
.
(28 February 2026)
CPNE3 promotes colorectal cancer progression by regulating KIF4-mediated autophagy
Journal of Gastrointestinal Oncology
2026;
17
(1)
:17
.
(28 February 2026)
The EZH2-NEAT1 epigenetic axis promotes cuproptosis sensitivity and modulates cancer cell migration in colorectal cancer
Journal of Gastrointestinal Oncology
2026;
17
(1)
:18
.
(28 February 2026)
Short- and long-term outcomes after laparoscopic and open liver resection for combined hepatocellular-cholangiocarcinoma patients: a propensity score-matched study
Journal of Gastrointestinal Oncology
2026;
17
(1)
:19
.
(28 February 2026)
Separation of liver focal nodular hyperplasia (FNH) and liver malignant tumors by a combination of T2-weighted imaging signal and three diffusion magnetic resonance metrics of diffusion-derived vessel density, slow diffusion coefficient, and apparent diffusion coefficient
Journal of Gastrointestinal Oncology
2026;
17
(1)
:20
.
(28 February 2026)
Barcelona Clinic Liver Cancer strategy adherence in hepatocellular carcinoma and its influence on long-term outcomes
Journal of Gastrointestinal Oncology
2026;
17
(1)
:21
.
(28 February 2026)
ΔSII-based nomogram for prognosis prediction after radical resection for hepatocellular carcinoma
Journal of Gastrointestinal Oncology
2026;
17
(1)
:22
.
(28 February 2026)
Hedyotis diffusa Willd suppresses hepatocellular carcinoma tumor-stromal interactions by inactivating cancer-associated hepatic stellate cells
Journal of Gastrointestinal Oncology
2026;
17
(1)
:23
.
(28 February 2026)
Clinical model for predicting overall survival outcomes in individuals with hepatocellular carcinoma: a retrospective cohort analysis
Journal of Gastrointestinal Oncology
2026;
17
(1)
:24
.
(28 February 2026)
Global research trends and foci of ablation therapies for liver tumours: a scientometric study
Journal of Gastrointestinal Oncology
2026;
17
(1)
:25
.
(28 February 2026)
FTSJ1-mediated IL1RN mRNA instability promotes inflammation-driven hepatocellular carcinoma
Journal of Gastrointestinal Oncology
2026;
17
(1)
:26
.
(28 February 2026)
Development and internal validation of a predictive nomogram for early postoperative bacterial infections following liver transplantation in patients with hepatocellular carcinoma
Journal of Gastrointestinal Oncology
2026;
17
(1)
:27
.
(28 February 2026)
Identification of mitochondrial-related subtypes and development of a prognostic model for pancreatic ductal adenocarcinoma
Journal of Gastrointestinal Oncology
2026;
17
(1)
:28
.
(28 February 2026)
Real-world comparative effectiveness of FOLFIRINOX versus gemcitabine/nab-paclitaxel in metastatic pancreatic cancer: prognostic impact of metastatic site and burden in a Middle Eastern cohort
Journal of Gastrointestinal Oncology
2026;
17
(1)
:29
.
(28 February 2026)
Review Article
The APOBEC3 family: a narrative review of an alternative therapeutic agent for hepatitis B virus-induced hepatocellular carcinoma
Journal of Gastrointestinal Oncology
2026;
17
(1)
:30
.
(28 February 2026)
Study Protocol
DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer
Journal of Gastrointestinal Oncology
2026;
17
(1)
:31
.
(28 February 2026)
Case Series
Partial splenic embolization plus antitumor therapy for treating patients with hepatocellular carcinoma and splenomegaly: a case series study
Journal of Gastrointestinal Oncology
2026;
17
(1)
:32
.
(28 February 2026)
Case Report
A case report: Masson’s tumor (intravascular papillary endothelial hyperplasia) of the abdominal cavity
Journal of Gastrointestinal Oncology
2026;
17
(1)
:33
.
(28 February 2026)
Editorial Commentary
Beyond LEAP-015: the ongoing challenge of vascular endothelial growth factor inhibition in gastric cancer
Journal of Gastrointestinal Oncology
2026;
17
(1)
:34
.
(28 February 2026)
Checkpoint inhibition in advanced biliary tract cancer: progress, limitations, and the search for biomarker-driven strategies
Journal of Gastrointestinal Oncology
2026;
17
(1)
:35
.
(28 February 2026)
The role of chemoradiotherapy after induction in locally advanced pancreatic cancer: lessons learnt from CONKO-007
Journal of Gastrointestinal Oncology
2026;
17
(1)
:36
.
(28 February 2026)
In search of the best perioperative treatment for gastroesophageal cancer: is there a role for antiangiogenesis?
Journal of Gastrointestinal Oncology
2026;
17
(1)
:37
.
(28 February 2026)
Anlotinib and penpulimab in advanced hepatocellular carcinoma: a new contender emerges
Journal of Gastrointestinal Oncology
2026;
17
(1)
:38
.
(28 February 2026)
Regorafenib in refractory gastric cancer: modest median, meaningful milestone
Journal of Gastrointestinal Oncology
2026;
17
(1)
:39
.
(28 February 2026)
Antiangiogenic therapy for advanced biliary tract cancers: promising or illusory?
Journal of Gastrointestinal Oncology
2026;
17
(1)
:40
.
(28 February 2026)
Development of systemic chemotherapy starting from comparison with best supportive care: commentary on the INTEGRATE IIa phase III study
Journal of Gastrointestinal Oncology
2026;
17
(1)
:41
.
(28 February 2026)
Bevacizumab in biliary tract cancer: a clinical catalyst in the era of chemo-immunotherapy?
Journal of Gastrointestinal Oncology
2026;
17
(1)
:42
.
(28 February 2026)
Editorial
Biology before stage in advanced gastric cancer: converting to cure in biomarker-selected patients
Journal of Gastrointestinal Oncology
2026;
17
(1)
:43
.
(28 February 2026)
Retraction
Retraction: HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis
Journal of Gastrointestinal Oncology
2026;
17
(1)
:44
.
(28 February 2026)
